Please assess the completion status of the following clinical trial:

Trial Title: Hysteroscopic Lymphatic Mapping for Endometrial Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with biopsy confirmed endometrial cancer who have been dispositioned to undergo total hysterectomy, bilateral salpingooophorectomy and lymph node staging.~2. Surgical procedures may be performed by either laparotomy or laparoscopy.~3. If computed tomography, magnetic resonance imaging, lymphangiography, or ultrasound has been performed for preoperative assessment, there must be no evidence of metastases. Imaging is not mandatory.~4. Patients who have signed an approved informed consent and authorization permitting release of personal health information.~Exclusion Criteria:~1. Patients with a preoperative diagnosis of grade I endometrioid adenocarcinoma of the uterus.~2. Patients with uterine papillary serous carcinoma.~3. Patients who have undergone endometrial ablation or a myomectomy within 1 year of the surgery for endometrial cancer.~4. Patients with known allergies to triphenylmethane compounds or technetium-99 radiocolloid.~5. Patients with a history of retroperitoneal surgery.~6. Patients with a history of pelvic radiation.~7. Patients with no lesion visible on hysteroscopy.~8. Patients with previous exposure to the tracer (to prevent risk of allergic reaction).

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intraoperative Lymphatic Mapping (Type: EXPERIMENTAL): Intraoperative sentinel lymph node identification (lymphatic mapping)

Based on this trial design, predict the completion outcome and termination type (if applicable).